NICE recommendation for Daklinza (daclatasvir) + sofosbuvir to treat hepatitis C- BMS
The National Institute for Health and Care Excellence (NICE) has recommended daclatasvir (Daklinza) from BMS in combination with sofosbuvir (Sovaldi) to treat genotype 1 or genotype 4 hepatitis C previously treated patients or those intolerant to treatment, without cirrhosis, over 12 weeks but not to treat genotype 3 patients.
Price is £8,172.61 for a 28 tablet pack at 60 mg each. Average cost over 12 weeks is £59,501 (~$119,000) for a 24 week course plus any additional costs for ribavirin (if needed).
BMS has objected, stating that 45% of hepatitis C patients in the UK have the genotype 3 condition which has faster disease progression and is more difficult to treat, and that there are fewer treatment options available for this group. NICE stated that the BMS estimates of SVR (sustained virological response) rates were uncertain and that the drug was not cost effective for genotype 3.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins